Core Points - BioArctic AB's founders and CEO have been awarded Uppsala University's Innovation and Entrepreneurship Prize for their contributions to addressing Alzheimer's disease [1][2][8] - The prize recognizes their groundbreaking research and successful commercialization of an academic discovery into an approved drug, lecanemab, which has the potential to significantly impact millions of lives [2][8] Company Overview - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease [11] - The company is known for developing Leqembi® (lecanemab), the first drug proven to slow the progression of early Alzheimer's disease and reduce cognitive impairment [11] - BioArctic collaborates with Eisai, a Japanese pharmaceutical company, to develop lecanemab and is actively pursuing approvals in multiple countries [6][11] Founders' Vision - The founders, Lars Lannfelt and Pär Gellerfors, aimed to establish BioArctic as a significant pharmaceutical company in Sweden, revitalizing the country's pharmaceutical industry [5] - Lars Lannfelt's research in the 1990s laid the foundation for the development of an antibody to combat Alzheimer's disease, leading to the establishment of BioArctic in 2003 [4][5] Drug Development and Approval - Lecanemab is currently approved in eleven countries, including the USA, Japan, and China, with additional approvals pending in 17 regions, including Europe [6] - The drug represents a significant advancement in the treatment of Alzheimer's disease, with the potential to change the lives of millions [2][11]

Core Viewpoint - A class action lawsuit has been filed against BioAge Labs, Inc. for alleged violations of federal securities laws related to misleading statements made during its IPO and subsequent trial discontinuation announcement [1][2]. Group 1: Lawsuit Details - The lawsuit pertains to BioAge's announcement on December 6, 2024, regarding the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, which contradicts earlier claims made during the IPO about the drug's potential in obesity therapy [2]. Group 2: Investor Information - Shareholders who purchased BioAge's securities during the IPO on September 26, 2024, are encouraged to contact the DJS Law Group before March 10, 2025, to participate in the lawsuit [1][3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 10, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [4] Group 3: Case Background - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, during its IPO, stating there were no safety concerns and expecting positive trial results [5] - BioAge discontinued the STRIDES Phase 2 study of azelaprag after subjects showed elevated liver enzyme levels, which were not disclosed in prior trials, leading to claims that the company's statements were false and misleading [6]

Core Viewpoint - A lawsuit has been filed against BioAge Labs, Inc. and its senior executives for potential violations of federal securities laws related to their initial public offering and subsequent disclosures regarding their clinical trials [1][2]. Company Overview - BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic products for metabolic diseases, particularly obesity [3]. Legal Context - The lawsuit claims violations under Sections 11 and 15 of the Securities Act of 1933, specifically concerning the registration statement for BioAge's IPO on September 26, 2024 [2]. - The case is currently pending in the U.S. District Court for the Northern District of California, titled Soto v. BioAge Labs, Inc., et al., No. 25-cv-196 [2]. Clinical Trial Details - BioAge's IPO documents highlighted the ongoing STRIDES Phase 2 trial of its lead product candidate, azelaprag, in combination with GLP-1R agonists for enhanced weight loss, with expectations for topline results in Q3 2025 [4]. - The company claimed collaboration with Eli Lilly and Company for the trial's design and execution, asserting no safety concerns at the time [4]. Trial Discontinuation - The STRIDES Phase 2 trial was discontinued due to safety concerns after subjects exhibited elevated liver enzyme levels, indicating potential organ damage [5]. - BioAge announced the discontinuation on December 6, 2024, leading to a significant stock price decline of over 76%, from $20.09 to $4.65 per share within three days [6].

NEW YORK, March 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=134581&from=4CLASS PERIOD: This lawsuit is on ...

Group 1 - The Schall Law Firm has filed a class action lawsuit against BioAge Labs, Inc. for violations of federal securities laws related to its IPO on September 26, 2024 [1] - The lawsuit claims that BioAge made false and misleading statements regarding its lead trial candidate, azelaprag, particularly concerning its safety and potential in obesity therapy [4] - The discontinuation of the STRIDES Phase 2 trial due to safety concerns was contrary to the claims made during the IPO, leading to investor damages when the truth was revealed [4] Group 2 - Investors who purchased BioAge's securities during the IPO are encouraged to contact the Schall Law Firm to discuss their rights [2] - The class in this case has not yet been certified, meaning potential class members are not yet represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025 deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court by March 10, 2025, to serve as lead plaintiff [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Background - The lawsuit alleges that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge discontinued the STRIDES Phase 2 study after subjects exhibited elevated liver enzyme levels, indicating potential organ damage, which was not disclosed in prior trials [6].

Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased BioAge stock during the IPO on September 26, 2024, with a lead plaintiff deadline set for March 10, 2025 [1]. - Allegations include that BioAge's registration statement and prospectus contained false or misleading statements regarding the STRIDES Phase 2 trial for azelaprag, specifically concerning liver transaminitis and safety concerns [2]. Group 2: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by March 10, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select counsel for the litigation [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit due to alleged violations of the Securities Act of 1933 related to its IPO, with claims that the offering documents were misleading regarding safety concerns and clinical trial expectations [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Soto v. BioAge Labs, Inc., allows purchasers of BioAge Labs stock from its IPO on September 26, 2024, to seek lead plaintiff status by March 10, 2025 [1][5]. - BioAge Labs sold 12.65 million shares at $18.00 per share during its IPO [2]. - The lawsuit alleges that the IPO documents falsely indicated no safety concerns and optimistic expectations for the STRIDES clinical trial [3]. Group 2: Impact of Clinical Trial Results - On December 6, 2024, BioAge Labs announced the discontinuation of the STRIDES Phase 2 study due to liver transaminitis observed in subjects, leading to a stock price drop of over 76% [4]. - By the time the class action lawsuit commenced, BioAge Labs stock was trading around $5.82 per share, significantly lower than the IPO price of $18.00 [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and has a strong track record in securities fraud cases, having recovered $6.6 billion for investors in related cases [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, of the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit related to the company's alleged misleading statements regarding its clinical trials [1]. Group 1: Class Action Details - Investors who purchased BioAge stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm for more information [3][7]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in connection with the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted as part of the trial's design and execution [5]. - The IPO suggested no safety concerns, but the company later discontinued the STRIDES Phase 2 study due to elevated liver enzyme levels in subjects, indicating potential organ damage [6]. Group 3: Allegations of Misleading Information - The lawsuit alleges that BioAge failed to disclose the potential for liver transaminitis from previous clinical trials and preclinical studies, making their statements in the registration statement materially misleading at the time of the IPO [6]. - When the true details about the safety concerns became public, investors reportedly suffered damages [6].